Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Literature DB >> 7042170

Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

M Eichelbaum.

Abstract

Mesh：

Substances：

Year: 1982 PMID： 7042170 DOI： 10.2165/00003088-198207010-00001

Source DB: PubMed Journal: Clin Pharmacokinet ISSN： 0312-5963 Impact factor: 6.447

× No keyword cloud information.

54 in total

1. THE PHYSIOLOGICAL BASIS OF CARDIAC ARRHYTHMIAS.

Authors: B F HOFFMAN; P F CRANEFIELD
Journal: Am J Med Date: 1964-11 Impact factor: 4.965

2. Polymorphism of carbon oxidation of drugs and clinical implications.

Authors: T P Sloan; A Mahgoub; R Lancaster; J R Idle; R L Smith
Journal: Br Med J Date: 1978-09-02

3. Genetic evidence for the involvement of different oxidative mechanisms in drug oxidation.

Authors: L A Wakile; T P Sloan; J R Idle; R L Smith
Journal: J Pharm Pharmacol Date: 1979-05 Impact factor: 3.765

4. Coronary care for myocardial infarction in diabetics.

Authors: N G Soler; B L Pentecost; M A Bennett; M G FitzGerald; P Lamb; J M Malins
Journal: Lancet Date: 1974-03-23 Impact factor: 79.321

5. Serum tolbutamide and chlorpropamide concentrations in patients with diabetes mellitus.

Authors: A Melander; G Sartor; E Wåhlin; B Scherstén; P O Bitzén
Journal: Br Med J Date: 1978-01-21

6. Pharmacogenetics: multiple interactions between genes and environment as determinants of drug response.

Authors: E S Vesell
Journal: Am J Med Date: 1979-02 Impact factor: 4.965

7. Inheritance of phenytoin hypometabolism: a kinetic study of one family.

Authors: M R Vasko; R D Bell; D D Daly; C E Pippenger
Journal: Clin Pharmacol Ther Date: 1980-01 Impact factor: 6.875

8. A method for studying drug metabolism in populations: racial differences in amobarbital metabolism.

Authors: W Kalow; B K Tang; D Kadar; L Endrenyi; F Y Chan
Journal: Clin Pharmacol Ther Date: 1979-12 Impact factor: 6.875

9. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors: M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal: Eur J Clin Pharmacol Date: 1979-09 Impact factor: 2.953

10. Comparative metabolism of benzo[a]pyrene and drugs in human liver.

Authors: J Kapitulnik; P J Popper; A H Conney
Journal: Clin Pharmacol Ther Date: 1977-02 Impact factor: 6.875

67 in total

1. Clinical pharmacology in Europe: an indispensible part of the health service. WHO Working Group on Clinical Pharmacology in Europe.

Authors:
Journal: Eur J Clin Pharmacol Date: 1988 Impact factor: 2.953

2. Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals.

Authors: E L Carey; H J Duff; D M Roden; R K Primm; G R Wilkinson; T Wang; J A Oates; R L Woosley
Journal: J Clin Invest Date: 1984-02 Impact factor: 14.808

3. Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.

Authors: P Dayer; L Balant; A Kupfer; R Striberni; T Leemann
Journal: Eur J Clin Pharmacol Date: 1985 Impact factor: 2.953

4. Tolbutamide 4-hydroxylase activity of human liver microsomes: effect of inhibitors.

Authors: H S Purba; D J Back; M L Orme
Journal: Br J Clin Pharmacol Date: 1987-08 Impact factor: 4.335

5. Carbamazepine metabolism in man. Induction and pharmacogenetic aspects.

Authors: M Eichelbaum; T Tomson; G Tybring; L Bertilsson
Journal: Clin Pharmacokinet Date: 1985 Jan-Feb Impact factor: 6.447

6. Human liver debrisoquine 4-hydroxylase: test for specificity toward various monooxygenase substrates and model of the active site.

Authors: T Wolff; L M Distlerath; M T Worthington; F P Guengerich
Journal: Arch Toxicol Date: 1987 Impact factor: 5.153